Fusion molecules of CTLA4 and IL-15

Provided herein are soluble fusion protein complexes, including domains from IL-15, IL-15 receptor, and alpha CTLA4 antibodies, for use in preventing, reducing the onset of, and/or treating cancer or an autoimmune disease or disorder in a subject. The methods provided herein comprise administering t...

Full description

Saved in:
Bibliographic Details
Main Authors OLSON CHRISTOPHER A, SOON-SHIONG PATRICK, TANAKA SATOSHI
Format Patent
LanguageChinese
English
Published 30.08.2024
Subjects
CHEMISTRY
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
Online AccessGet full text

Cover

More Information
Summary:Provided herein are soluble fusion protein complexes, including domains from IL-15, IL-15 receptor, and alpha CTLA4 antibodies, for use in preventing, reducing the onset of, and/or treating cancer or an autoimmune disease or disorder in a subject. The methods provided herein comprise administering to a subject a pharmaceutical composition comprising the soluble fusion protein complex. 本文提供了可溶性融合蛋白复合物，包括来自IL-15、IL-15受体和αCTLA4抗体的结构域，用于预防受试者中的癌症或自身免疫病或障碍、减少其发生和/或对其进行治疗。本文提供的方法包括向受试者施用包含该可溶性融合蛋白复合物的药物组合物。
Bibliography:Application Number: CN20238017890